Stay updated on Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial
Sign up to get notified when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.

Latest updates to the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page
- Check2 days agoChange DetectedA revision tag on the page is updated to v3.6.2, replacing the previous v3.6.0, indicating a small update to the page or its underlying system.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now shows a recruitment-status line 'No longer looking for participants' and adds new help/navigation items such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study', with the Intervention/Treatment label introduced. Additionally, revision metadata updates to v3.6.0 and the label formatting changes from 'Intervention / Treatment' to 'Intervention/Treatment' to standardize presentation.SummaryDifference0.2%

- Check24 days agoChange DetectedThe page now shows revision v3.5.5, replacing the previous v3.5.4. This reflects a minor platform update that does not affect the study details or other visible content.SummaryDifference0.0%

- Check45 days agoChange DetectedAdded revision tag v3.5.4 and removed v3.5.3, indicating an update to the page's underlying revision/version.SummaryDifference0.0%

- Check67 days agoChange DetectedThe page footer revision was updated from “Revision: v3.5.0” to “Revision: v3.5.3,” reflecting a ClinicalTrials.gov site/version release rather than any change to the study information.SummaryDifference0.0%

- Check102 days agoChange Detected- Added Revision: v3.5.0 and removed Revision: v3.4.2.SummaryDifference0.0%

Stay in the know with updates to Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.